Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized enoxaparin to prevent DVT after joint replacement
ChiCTR2600121160Phase 4Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of enoxaparin in deep vein thrombosis (DVT) (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Incidence of deep vein thrombosis (DVT) at 7 days postoperatively. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
enoxaparin
03
Conditions
deep vein thrombosis (DVT)
Beyond the preview
Go deeper on ChiCTR2600121160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121160.